中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2014年
21期
92-94,95
,共4页
李点玲%何桦%赵祝香%张颖
李點玲%何樺%趙祝香%張穎
리점령%하화%조축향%장영
N-乙酰半胱氨酸%茶碱%慢性阻塞性肺病
N-乙酰半胱氨痠%茶堿%慢性阻塞性肺病
N-을선반광안산%다감%만성조새성폐병
N-acetylcysteine%Theophylline%Chronic obstructive pulmonary disease
目的：旨在探讨抗氧化剂N-乙酰半胱氨酸联合小剂量茶碱治疗轻中度稳定期COPD患者的疗效及安全性。方法：将133例稳定期轻中度COPD患者随机分为试验组63例和对照组70例，试验组服用茶碱缓释片（0.1 g，每12小时一次）+N-乙酰半胱氨酸（NAC）（600 mg，1次/d）；对照组服用茶碱缓释片（0.1 g，每12小时一次）。疗程均为24周。治疗前、治疗24周后，对患者行肺功能检测及CAT评分，治疗期间记录疾病急性加重的次数及是否出现不良事件。结果：治疗24周后与治疗前比较，两组的肺功能各项指标均无明显改变（P<0.05）。两组CAT评分较治疗前均有所改善，试验组CAT评分改善情况优于对照组，且试验组AECOPD发生次数明显少于对照组，差异均有统计学意义（P<0.05）。安全性方面，用药期间的不良事件主要表现为胃肠道不适、手震、心悸、皮疹等。以上症状均较轻，两组间不良事件发生率比较差异均无统计学意义（P>0.05）。结论：N-乙酰半胱氨酸联合小剂量茶碱能有效改善COPD患者的生活质量，对于轻中度稳定期的COPD患者来说，是行之有效的安全的治疗方法。
目的：旨在探討抗氧化劑N-乙酰半胱氨痠聯閤小劑量茶堿治療輕中度穩定期COPD患者的療效及安全性。方法：將133例穩定期輕中度COPD患者隨機分為試驗組63例和對照組70例，試驗組服用茶堿緩釋片（0.1 g，每12小時一次）+N-乙酰半胱氨痠（NAC）（600 mg，1次/d）；對照組服用茶堿緩釋片（0.1 g，每12小時一次）。療程均為24週。治療前、治療24週後，對患者行肺功能檢測及CAT評分，治療期間記錄疾病急性加重的次數及是否齣現不良事件。結果：治療24週後與治療前比較，兩組的肺功能各項指標均無明顯改變（P<0.05）。兩組CAT評分較治療前均有所改善，試驗組CAT評分改善情況優于對照組，且試驗組AECOPD髮生次數明顯少于對照組，差異均有統計學意義（P<0.05）。安全性方麵，用藥期間的不良事件主要錶現為胃腸道不適、手震、心悸、皮疹等。以上癥狀均較輕，兩組間不良事件髮生率比較差異均無統計學意義（P>0.05）。結論：N-乙酰半胱氨痠聯閤小劑量茶堿能有效改善COPD患者的生活質量，對于輕中度穩定期的COPD患者來說，是行之有效的安全的治療方法。
목적：지재탐토항양화제N-을선반광안산연합소제량다감치료경중도은정기COPD환자적료효급안전성。방법：장133례은정기경중도COPD환자수궤분위시험조63례화대조조70례，시험조복용다감완석편（0.1 g，매12소시일차）+N-을선반광안산（NAC）（600 mg，1차/d）；대조조복용다감완석편（0.1 g，매12소시일차）。료정균위24주。치료전、치료24주후，대환자행폐공능검측급CAT평분，치료기간기록질병급성가중적차수급시부출현불량사건。결과：치료24주후여치료전비교，량조적폐공능각항지표균무명현개변（P<0.05）。량조CAT평분교치료전균유소개선，시험조CAT평분개선정황우우대조조，차시험조AECOPD발생차수명현소우대조조，차이균유통계학의의（P<0.05）。안전성방면，용약기간적불량사건주요표현위위장도불괄、수진、심계、피진등。이상증상균교경，량조간불량사건발생솔비교차이균무통계학의의（P>0.05）。결론：N-을선반광안산연합소제량다감능유효개선COPD환자적생활질량，대우경중도은정기적COPD환자래설，시행지유효적안전적치료방법。
To explore the treatment effect in COPD with N-acetyl cysteine and small dose of theophylline. Method:133 mild-to-moderate COPD patients were randomly divided into the treatment group for 63 cases and the control group for 70 cases. The treatment group patients taken theophylline 0.1 g q12 h+N-acetylcysteine(NAC) 600 mg qd. The control group was given theophylline 0.1 g q12 h. Before and after 24 weeks treatment pulmonary function test and CAT scores of the two groups were detected. The numbers of AECOPD and adverse events were recorded. Result:In terms of lung function index,two groups of 24 weeks after treatment was compared with before treatment, there was no significant difference between the two groups(P>0.05). The quality of life,CAT score of two groups after treatment were improved,CAT score in the treatment group were superior to those in the control group,and the incidences of AECOPD in the treatment group significantly less than those in the control group(P<0.05). The main adverse events were gastrointestinal discomfort,hand shake,heart palpitations,skin rash,etc. These symptoms were lighter,incidence of adverse events between the two groups was no statistically significant difference(P>0.05).Conclusion:N-acetyl cysteine in combination with small dose of theophylline can effectively improve the quality of life of patients with COPD. For patients with mild-to-moderate COPD,N-acetyl cysteine in combination with small dose of theophylline is a safe and effective treatment method.
